July 25, 2025

Tofacitinib Curbs Inflammation, Not Thrombosis Risk

Tofacitinib dampens inflammatory cytokine production in rheumatoid arthritis models but fails to counteract endothelial prothrombotic responses, highlighting ongoing cardiovascular safety concerns.

Conexiant

July 15, 2025

Genetic Markers Don’t Guide RA Drug Choice

A large UK study found no significant difference in treatment effectiveness between abatacept and adalimumab for rheumatoid arthritis, regardless of patients’ HLA-DRB1 genetic profiles.

Conexiant

July 15, 2025

Cementless Knee Implants Show Superior Outcomes in Patients With Obesity

A new review comparing knee implant methods in obese patients finds cementless fixation may improve implant survival and reduce loosening compared with cemented approaches, especially in patients with BMI ≥35 kg/m².

Conexiant

July 15, 2025

Methotrexate Shows No Knee OA Symptom Benefit, Study Finds

A 52-week randomized clinical trial found no significant difference between methotrexate and placebo in reducing pain or effusion-synovitis in patients with inflammatory knee osteoarthritis.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

June 12, 2025

Gene Variants Linked to CPPD Risk

A large genetic study in U.S. veterans has identified ENPP1 and RNF144B as genes associated with calcium pyrophosphate deposition disease, suggesting potential for targeted treatment approaches.

Conexiant

April 30, 2025

New AI Sensor Diagnoses Osteoarthritis and Rheumatoid Arthritis

A new AI-assisted gold sensor distinguished osteoarthritis from rheumatoid arthritis with 98.1% accuracy by analyzing synovial fluid, offering a fast, noninvasive diagnostic option, researchers report.

Conexiant

April 18, 2025

Gout Remission Linked to Lower Urate, Fewer Flares

Remission in gout after urate-lowering therapy was seldom after 1 but high after 5 years, finds a five-year NOR-Gout study tracking 211 patients.

Conexiant

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant